Biling Weitong Granules combined with western medicine in the treatment of peptic ulcer clinical pilot trial

Biling Weitong Granules combined with western medicine in the treatment of peptic ulcer randomized, double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022749

Enrollment

Unknown

Registered

2019-04-24

Start date

2019-05-16

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic ulcer

Interventions

Treatment Group:Biling Weitong Granules combined with Pantoprazole sodium enteric-coated tablets

Control Group:Placebo Granules combined with Pantoprazole sodium enteric-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Conforms to the diagnosis standard of peptic ulcer; 2. Active stage ulcer 3. Aged 18 to 65 years, male or female; 4. Endoscopic ulcer diameter is 0.3~1cm; 5. Voluntary and signed ICF.

Exclusion criteria

Exclusion criteria: 1. Ulcers caused by non-steroidal anti-inflammatory drugs, aspirin, etc.; 2. Peptic ulcers in the H phase (healing phase) and S phase (scarring phase); 3, Special types of peptic ulcers, such as esophageal ulcers, giant ulcers, complex ulcers, linear ulcers, frost-like ulcers and other diseases induced ulcers; 4. Patients with a history of tumor, stomach, and duodenal surgery; 5, Combined with other stomach and digestive diseases, such as esophageal varices bleeding, reflux esophagitis, Barrett's esophagus, gastric mucosal tear, acute gastric mucosal lesions; 6. The hepatobiliary B ultrasound examination found abnormal, accompanied by liver, gallbladder, spleen, pancreas, kidney disease; 7. Combined with peptic ulcer complications, such as pyloric obstruction, perforation, hemorrhage and cancer; 8. Take antacids, gastric mucosal protective agents and related Chinese medicines within 2 months before the test or in the past 3 months to participate in clinical trials; 9. Combined with severe cardiac insufficiency, liver and kidney (detection index ALT/AST exceeded the normal value of the upper limit of 1.5 times) function; 10. Pregnancy or lactating women; 11. Allergic to the medicine composition of the preparation; 12. The investigator think that is not suitable to participate in clinical trial.

Design outcomes

Primary

Measure	Time frame
Endoscopic mucosal healing area;VAS score of pain intensity and frequency;	—

Secondary

Measure	Time frame
Pain disappearance rate and disappearance time;Endoscopic mucosal healing quality;Clinical symptom score;Hp eradication rate;	—

Countries

China

Contacts

Public ContactNonghua Lyu

lunonghua@163.com+86 13707086809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026